News

The Food and Drug Administration approved filgrastim-aafi (Nivestym), a biosimilar to filgrastim (Neupogen), for all eligible indications of the original product.

This hike marks the fifth continent to be visited by a Moving Mountains for Multiple Myeloma team.

The FDA has approved the oral IDH1 inhibitor ivosidenib (Tibsovo) for the treatment of adult patients with relapsed/refractory IDH1-mutant acute myeloid leukemia (AML).

The FDA has granted a breakthrough therapy designation to atezolizumab (Tecentriq) for use in combination with bevacizumab (Avastin) as a first-line treatment for patients with advanced or metastatic hepatocellular carcinoma (HCC).

The FDA has granted a priority review to antibody-drug conjugate sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer following at least 2 prior therapies for metastatic disease.

The US Food and Drug Administration (FDA) approved two ribociclib (Kisqali) combination treatments for subsets of advanced breast cancer in less than a month using a pilot process called the Real-Time Oncology Review.

Inadequate oversight has distorted the noble intent of the 340B Drug Pricing Program, transforming it into a perverse profit generator for many of America’s tax-exempt hospitals.

Treatment with niraparib (Zejula) demonstrated durable responses among women with relapsed or refractory ovarian cancer regardless of BRCA mutation, study shows.

If the Senate’s version of the Department of Defense Appropriations Act, 2019 is signed into law, young adults could lose millions of dollars of support for AYA-specific research.

Clinicians at Rush University Medical Center identified the possibility that folate deficiency could be an adverse event related to olaparib (Lynparza) women take for relapsed ovarian cancer, and recommend further studies.

The FDA has approved enzalutamide (Xtandi) for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC).

Not enough discussions are occurring between oncologists and patients with advanced cancer around goals of care.

Based on the identification of 6 gene variations that make carriers susceptible to developing medulloblastoma and possibly other cancers, researchers have proposed subgroup-based counseling and screening recommendations.

The frontline combination use of atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) yielded a significant reduction in the risk for disease progression or death compared with nab-paclitaxel alone in patients with metastatic or unresectable locally advanced triple-negative breast cancer (TNBC).

CURE Media Group

The FDA granted an accelerated approval to the immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for use in adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

The FDA granted a priority review to pembrolizumab (Keytruda), an anti-PD-1 therapy, for the treatment of previously treated patients with advanced hepatocellular carcinoma.

Even among former smokers who have not smoked in more than 15 years, there is more than a minimal risk of lung cancer.

Patients with nonmetastatic castration-resistant prostate cancer experienced a 94% reduction in their risk of PSA progression following apalutamide (Erleada) treatment, according to a posthoc analysis from the phase III SPARTAN trial.

Patients with heavily pretreated metastatic or advanced gastric cancer who received TAS-102 (trifluridine/tipiracil; Lonsurf) saw a significant overall survival benefit, according to phase III study findings presented at the 2018 World Gastrointestinal Cancer Congress.

These are the most popular stories posted on Oncology Nursing News in the month of June.

The American Cancer Society recently updated its guidelines to lower the age to start colorectal cancer screening to 45. Nurses will play a vital role in implementing this important change.

Nurses treating young patients with cancer should be aware of the American Society of Clinical Oncology's updated guidelines and recommendations on fertility preservation, which were released in April 2018.

The partners will collaborate to empower the lung cancer community through educational efforts.

The FDA granted a priority review to the anti-PD-1 agent pembrolizumab (Keytruda) in combination with chemotherapy as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 expression.

Standardized and focused education for patients receiving CAR T-cell therapy and their caregivers should be part of discharge procedures.

The FDA granted a priority review to a new drug application for glasdegib, an investigational oral smoothened inhibitor, for the treatment of adult patients with previously untreated acute myeloid leukemia in combination with low-dose cytarabine, a type of chemotherapy.

The FDA has approved the combination of the BRAF inhibitor encorafenib (Braftovi) and the MEK inhibitor binimetinib (Mektovi) for the treatment of patients with BRAF-mutant unresectable or metastatic melanoma, as detected by an FDA-approved test.

This year, the Pancreatic Cancer Action Network (PanCAN) awarded 9 grants to 12 researchers at 11 institutions in the US, Canada, and France, totaling $4.2 million.